The FDA is adapting regulations to manage AI’s rapid development in healthcare, focusing on patient safety and the life cycle of AI tools. This review emphasizes the need for continuous monitoring to ensure AI performs effectively in clinical settings.
Gold Flora’s Q2: A Mixed Bag For Cannabis With EBITDA Down $2M, Margins Up To 57%
Gold Flora’s Q2: A Mixed Bag For Cannabis With EBITDA Down $2M, Margins Up To 57% Gold Flora (OTC:GRAM) reported Q2 2024 sales of $31.6